BACKGROUND:Hair loss remains a global concern for both men and women. AIMS:This study assessed the efficacy and safety of a proprietary extract of bioactive fatty acids from saw palmetto (Serenoa repens) for treating self-perceived thinning hair in healthy adult men and women (SEREVELLE, Valensa International; Eustis, FL). METHODS:This 6-month, randomized, double-blind, placebo-controlled study assessed the beneficial effects of daily active treatment (n = 40) vs. placebo (n = 20) on several hair growth parameters. RESULTS:Active treatment of SEREVELLE significantly outperformed placebo on all primary endpoints at Day 180. Mean (SD) change in baseline total terminal hair count was +18.6 (29.6) with active vs. -10.1 (30.5) with placebo (p < 0.001; 283% greater improvement). Total vellus hair count increased +6.6 (15.6) vs. -2.1 (15.7) (p < 0.05; 414% greater improvement). Total hair density rose +25.1 (27.7) vs. -12.2 (38.8) (p < 0.001; 306% greater improvement). Subgroup analyses at Day 180 corroborated these advantages: across populations, between-group differences in mean change favored active for subgroup of men, with total terminal hair count (p = 0.003), total vellus hair count (p < 0.001), and total hair density (p < 0.001). In menopausal women, active produced significant placebo-adjusted gains in total terminal hair count (p < 0.05) and total hair density (p < 0.01), with a nonsignificant numerical advantage for total vellus hair count. There were no treatment-related adverse events. CONCLUSION:The daily use of a proprietary saw palmetto (Serenoa repens) extract safely and effectively promotes hair growth in men and women with self-perceived thinning hair.
Background: RelabotulinumtoxinA (relaBoNT-A) is a novel, complex-free, ready-to-use liquid BoNT-A for aesthetic use. Methods: This double-blind, Phase 3b study evaluated long-term (12-month) efficacy, satisfaction, safety, and time to onset of effect of relaBoNT-A for glabellar lines (GLs). Subjects were randomized 3:1 to a single dose of 50 U relaBoNT-A or placebo. Results: RelaBoNT-A was superior to placebo at Month 1 based on subject-reported Global Aesthetic Improvement Scale (GAIS) responder rates at maximum frown (primary endpoint), 92.9% (92/99 subjects) versus 9.1% (3/33 subjects), p<0.001. GAIS response after relaBoNT-A treatment remained high through Months 9 (42.7%) and 12 (37.8%), as did investigator-assessed GL severity (GL-ILA) ≥1-grade improvement at maximum frown at Months 6 (57.4%), 9 (28.1%), and 12 (12.2%). GAIS and GL-ILA showed onset of effect in 39.8% and 43.9% of relaBoNT-A-treated subjects within 1 day. Investigators reported increased confidence in dosing consistency with the ready-to-use product at baseline (98.0% relaBoNT-A vs. 100% placebo), and that they could achieve consistent (99.0% vs. 64.5%) and natural-looking results (98.0% vs. 64.5%) at Month 1. Subject satisfaction was higher for relaBoNT-A than placebo from Day 1 through Month 12. Two-thirds of subjects preferred treatment with relaBoNT-A to prior treatments with powder BoNT-As. Treatment-related adverse events (all mild) occurred in 8.1% of subjects. Conclusions: RelaBoNT-A showed rapid onset of effect from Day 1, with duration of effect through Month 6 for most subjects, and beyond 6 months for some. Injectors were highly satisfied with product usability, and subjects remained satisfied through Month 12. Treatment was well tolerated.